Literature DB >> 2672823

Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats.

P J Baker1, R F Ochi, M Schulze, R J Johnson, C Campbell, W G Couser.   

Abstract

To study the possible role of the complement membrane attack complex, C5b-9, in an experimental rat model that is morphologically indistinguishable from membranous nephropathy in man (passive Heymann nephritis [PHN]), an antibody to rat C6 was used to deplete C6 levels to less than 5% of pretreatment values (C6D) during disease development. C3, C7, C8, and C9 levels were not different in C6D and control rats. After injection of nephritogenic quantities of 125I-anti-Fx1A antibody, the kinetics of disappearance of labeled IgG from the blood were identical in the complement deficient and sufficient groups, and glomerular deposition of 125I-antibody was the same in both groups at 5 days. Glomerular deposits of sheep IgG and C3 were also similar in C6D and controls, but glomerular deposits of C6 and C5b-9 neoantigens were markedly reduced or absent in C6 depleted rats. However, despite equivalent antibody deposits, proteinuria was abolished in C6D rats compared with normocomplementemic controls. Similar results were obtained when F(ab')2 anti-rat C6 IgG was used to deplete C6 during development of PHN. These results demonstrate that C6 is required for the development of the increased glomerular permeability that occurs in PHN, presumably because C6 is required for formation of C5b-9. We conclude that glomerular injury in the PHN model of membranous nephropathy in the rat is mediated by C5b-9.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2672823      PMCID: PMC1880216     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Mediation of immunologic glomerular injury.

Authors:  C G Cochrane
Journal:  Transplant Proc       Date:  1969-12       Impact factor: 1.066

2.  Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen.

Authors:  S Adler; D J Salant; J E Dittmer; H G Rennke; M P Madaio; W G Couser
Journal:  Kidney Int       Date:  1983-06       Impact factor: 10.612

3.  Persistence of passively transferred goat F(ab')2 antibody fragments in the circulation of rodents.

Authors:  S J Nelson; D D Manning
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

4.  Experimental glomerulonephritis in the isolated perfused rat kidney.

Authors:  W G Couser; D R Steinmuller; M M Stilmant; D J Salant; L M Lowenstein
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

5.  A new role for complement in experimental membranous nephropathy in rats.

Authors:  D J Salant; S Belok; M P Madaio; W G Couser
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

6.  Experimental membranous glomerulonephritis in rats. Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals.

Authors:  D J Salant; C Darby; W G Couser
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

7.  Apparent escape rate of RIHSA and 51Cr-labeled erythrocytes from the blood of volume-expanded rats.

Authors:  U Ackermann
Journal:  Am J Physiol       Date:  1978-05

8.  Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease.

Authors:  R J Falk; A P Dalmasso; Y Kim; C H Tsai; J I Scheinman; H Gewurz; A F Michael
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

9.  Immunoadsorbent affinity purification of the fifth component (C5) of human complement and development of a highly sensitive hemolytic assay.

Authors:  R A Wetsel; M A Jones; W P Kolb
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

10.  Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats.

Authors:  D Kerjaschki; M G Farquhar
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  35 in total

Review 1.  Complement and the Kidney: An Overview.

Authors:  Joshua M Thurman
Journal:  Adv Chronic Kidney Dis       Date:  2020-03       Impact factor: 3.620

Review 2.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

3.  Experimental Models of Membranous Nephropathy.

Authors:  J Ashley Jefferson; Jeffrey W Pippin; Stuart J Shankland
Journal:  Drug Discov Today Dis Models       Date:  2010

Review 4.  Molecules Great and Small: The Complement System.

Authors:  Douglas R Mathern; Peter S Heeger
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 8.237

Review 5.  Mechanisms of immune-deposit formation and the mediation of immune renal injury.

Authors:  Masaomi Nangaku; William G Couser
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

Review 6.  Membrane signaling by complement C5b-9, the membrane attack complex.

Authors:  A Nicholson-Weller; J A Halperin
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 7.  Membranous nephropathy. Insights from Heymann nephritis.

Authors:  T Cavallo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 8.  Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.

Authors:  P Ronco; H Debiec
Journal:  Semin Immunopathol       Date:  2007-09-26       Impact factor: 9.623

9.  Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.

Authors:  J W Pippin; Q Qu; L Meijer; S J Shankland
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

10.  Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.